Monopar announces promising preclinical data for MNPR-101 radiopharma; Phase 1 trial in Australia cleared

Monopar Therapeutics

MNPR-101 targets uPAR, expressed in majority of triple-negative breast, colorectal, and pancreatic cancers.
Optimized MNPR-101-Zr imaging agent shows increased tumor uptake and reduced healthy tissue uptake in PET studies.
Single injection of MNPR-101 conjugated to Ac-225 or other therapeutic isotope led to near complete tumor elimination in mouse models.
Received HREC clearance in Australia to start Phase 1 dosimetry trial of MNPR-101-Zr in advanced cancer patients.
Company plans to present results at an upcoming scientific meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.